Management of a case of Hepatitis B-associated Hepatocellular Carcinoma with Pleural Effusion in a middle-aged South Indian manDr. Sutanu PatraView Details
Health related disruptions due to COVID 19 pandemic in patients chronically infected with hepatitis B virus (HBV)Dr. Yeshika BhatiaView Details
Therapeutic Plasma Exchange in Patients with Hepatitis B Flare – associated Acute-on-Chronic Liver Failure: a Case Series StudyDr. Vo Huy VanView Details
Association of HLA-A*3101 with Carbamazepine induced idiosyncratic drug reactions in patients diagnosed with epilepsyDr. Vivek Kumar GargView Details
The Association between Interferon-gamma +874 T/A Polymorphism and Susceptibility of Chronic Hepatitis B with Liver Cirrhosis : An Update Meta AnalysisDr. Rizki FebriawanView Details
Risk of Multiple Drug Interactions Potentially Linked to Safety in Patients Receiving Pangenotypic Direct-acting Antivirals for the Treatment of Hepatitis CDr. Olivia NgView Details
Serum Alpha-Fetoprotein (AFP), Alpha-Fetoprotein Lens Culinaris Agglutinin 3 (AFP-L3) And Des-Gamma Carboxyprothrombin (DCP) Responses for Monitoring Treatment Outcomes in Patients With Hepatocellular Carcinoma Treated By Transarterial ChemoembolizationDr. Min Aung ShanView Details
Non-Hepatic Reservoir for Hepatitis Delta Virus (HDV) Identified in Human Salivary Gland. Is This Alternative Reservoir a Risk Factor for HBV Co-Infection?Dr. Matthew HestermanView Details
Socioeconomic Susceptibility to Depression in Patients with Chronic Hepatitis B infection in a developing countryDr. Jafferi Syed Khawar AbbasView Details
CD4+ T-Lymphocytes Count, HBe Ag Prevalence and Liver Transaminases Levels Among Apparently Healthy Individuals Tested Positive for Hepatitis B Viral Infection During 2015 World Hepatitis Day in SokotoDr. Bello Bala HaliView Details
Safety and Efficacy of Bulevirtide Monotherapy and in Combination with Peginterferon alfa-2a in Patients with Chronic Hepatitis Delta: 24-week Interim Data of MYR204 Phase 2b StudyDr. Jacques YuView Details
Switching from TDF and/or Other OAV to TAF in Virally Suppressed Chronic Hepatitis B Patients with Hepatic Impairment: Final 2 Year Efficacy and Safety Results from a Phase 2 Open-Label StudyDr. Jacques YuView Details
Improved Bone and Renal Parameters Across Multiple Chronic HBV (CHB) Patient Types Treated with Tenofovir Alafenamide (TAF) versus Tenofovir Disoproxil Fumarate (TDF)Dr. Jacques YuView Details
Safety and Efficacy at 4 Years in Post-liver Transplant Patients with Chronic Kidney Disease Receiving Tenofovir Alafenamide (TAF) For HBV ProphylaxisDr. Jacques YuView Details
Long-term Efficacy and Safety of Tenofovir Disoproxil Fumarate (TDF) in Children with Chronic Hepatitis B (CHB): Final Results from a Placebo-Controlled TrialDr. Jacques YuView Details
